Integrin alphavbeta3 – a vitronectin receptor – has been implicated in the pathophysiology and progression of several malignant tumors, such as melanoma [13,14], glioma [15], ovarian [16], prostate [17] and breast cancer [18,19]. Here, ITGAV is linked to melanoma.